Evan Buckmiller, DO
Child & Adolescent Psychiatry · Columbia, MONPI 1396361853
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 33.7% of the total. Reporting peaked in 2022 at $186 and has fallen 85.3% since, to $27 in 2024.
Across 19 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$133
- Indivior Inc.$65
- Johnson & Johnson$41
- AbbVie$34
- E.r. Squibb & Sons, L.L.C.$27
- Corium, LLC$24
- plus $70 from 4 others
What the payments were for
- Food & beverage$36793%
- Education$277%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $133 |
| Indivior Inc. | 4 | $65 |
| Johnson & Johnson | 3 | $41 |
| AbbVie | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Corium, LLC | 2 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$100
How this compares
$394 in reported general payments places this provider in the 55th percentile of 90 child & adolescent psychiatry providers in Missouri.
See all child & adolescent psychiatry providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 12 | $2,914 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Columbia
- Syed ImamColumbia$2K
- Ryan KavalierColumbia$453
- Garima SinghColumbia$237
- Sultana JahanColumbia$225
- Lakshmi RavipatiColumbia$206
- Arpit AggarwalColumbia$146
- Brandon BrewerColumbia$132
- Ginger NicolSaint Louis$77K
- Jeffrey SchulmanSaint Louis$62K
- Joshua WilsonSaint Louis$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.